RxDoctor Payments Data

John Schmittner, MD

Cardiovascular Disease · Temple, TXNPI 1275891913

Payments from drug & device makers

$9,869in general payments, 2019–2025

Across 143 payments — averaging $69.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Abiomed$2K
  • AstraZeneca$272
  • Alnylam Pharmaceuticals Inc.$224
  • Merck$205
  • Pfizer$180
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$5005%
  • Speaking & faculty fees$3,00030%
  • Travel & lodging$1,22412%
  • Food & beverage$5,08151%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,869 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$35,197
Medicare patients
174
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin327$352,982
EntrestoSacubitril/Valsartan286$340,982
FarxigaDapagliflozin Propanediol29$39,520
EliquisApixaban28$34,614
Metoprolol Succinate244$4,620
Spironolactone391$4,400
Torsemide124$3,708
Atorvastatin Calcium112$2,309
Losartan Potassium111$1,420
Isosorbide Dinitrate24$1,321
Hydralazine Hcl44$1,239
Bisoprolol Fumarate17$1,224
Bumetanide17$934
Potassium Chloride45$934
Rosuvastatin Calcium34$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$98$352,982327 claims
NovartisEntresto$83$340,982286 claims
AstraZenecaFarxiga$272$39,52029 claims
PfizerEliquis$180$34,61428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →